ICMR Develops Indigenous Vaccine Against H5N1 Bird Flu Virus
NEW DELHI: The Indian Council for Medical Research (ICMR) is taking significant strides in public health with the development of an indigenous vaccine aimed at combating the H5N1 bird flu virus. This highly pathogenic strain poses a threat not only to avian species but, in rare instances, can also affect humans.
Background on H5N1 Bird Flu
Avian influenza H5N1 has been responsible for several outbreaks across India in 2021, 2023, and 2024, predominantly impacting poultry and wild birds. The repercussions have been severe, resulting in substantial losses within the poultry industry and heightened public health concerns due to its potential to infect humans. The ICMR emphasizes that H5N1 infection in humans has a staggering case fatality rate exceeding 50%. While human cases are infrequent and generally occur through direct contact with infected birds, the severity of the illness necessitates ongoing vigilance.
Current Developments and Collaborations
ICMR has access to various strains of the virus available at the Pune-based National Institute of Virology and is seeking collaboration with companies for joint vaccine development. An Expression of Interest issued by ICMR indicates that partnering firms will be granted rights to further develop, manufacture, sell, and commercialize the vaccine technology.
Global Efforts and Future Outlook
In tandem with ICMR’s efforts, the World Health Organization (WHO) is working on a project to expedite the development and accessibility of H5N1 messenger RNA vaccine candidates, particularly for manufacturers in low- and middle-income countries. This collaborative approach underscores the global commitment to addressing the threat posed by H5N1.
Stay Informed and Prepared
As public health initiatives advance, it’s vital to stay informed about developments regarding avian influenza and other health-related matters. For exclusive deals and offers on health products, visit Looffers.com!
